Corneal Epithelial Allograft From Living-related Donor for LSCD

Exclusion Criteria

• •Recipients:
• •1. LSCD of mild degree, with less than 2 quadrants of neo-vessel invasion and without central cornea involvement;
• •2. LSCD by ocular surface disorders other than ocular burn;
• •3. Eyelids malposition;
• •4. The center corneal thickness\<450µm, the depth of corneal opacity \> 150µm;
• •5. High myopia with a spherical equivalent of -15.0 D or less;
• •6. Corneal or ocular surface infection within 30 days prior to study entry;
• •7. Ocular surface malignancy;
• •8. Uncontrolled diabetes with most recent Hemoglobin A1c greater than 8.5%;
• •9. Renal failure with creatinine clearance\< 25ml/min;
• •10. Alanine aminotransferase \> 40IU/L, or aspartate aminotransferase \> 40IU/L;
• •11. Platelet levels \< 150,000 or \> 450,000 per microliter;
• •12. Hemoglobin \< 12.0 g/dL (male) or \< 11.0 g/dL (female);
• •13. Prothrombin time \> 16s and activated partial thrombin time \> 35s in patients not accepting anticoagulant therapy; An international normalized ratio greater than 3 in patients accepting anticoagulant therapy;
• •14. Pregnancy (positive test) or lactation;
• •15. Participation in another simultaneous medical investigation or clinical trial;
• •16. Severe cicatricial eye disease; Conjunctival scarring with fornix shortening;
• •17. Ocular comorbidities that affect the prognosis of transplantation, such as advanced glaucoma or retinal diseases;
• •18. Severe dry eye disease as determined by Schirmer's test \< 2mm at least in one eye;
• •19. Any medical or social condition that in the judgment of the investigator would interfere with or serve as a contraindication to adherence to the study protocol or ability to give informed consent;
• •20. Signs of current infection, including fever and treatment with antibiotics;
• •21. Active immunological diseases;
• •22. History of allo-limbal transplantation, penetrating keratoplasty or anti-glaucoma filtering surgeries.
• •Donors:
• •1. Cornea diseases (epithelial defects, neovascularization, etc.);
• •2. Eyelids malposition;
• •3. The center corneal thickness\<450µm, the depth of corneal opacity \> 150µm;
• •4. High myopia with a spherical equivalent of -15.0 D or less;
• •5. Corneal or ocular surface infection within 30 days prior to study entry;
• •6. Ocular surface malignancy;
• •7. Uncontrolled diabetes with most recent Hemoglobin A1c greater than 8.5%;
• •8. Renal failure with creatinine clearance\< 25ml/min;
• •9. Alanine aminotransferase \> 40IU/L, or aspartate aminotransferase \> 40IU/L;
• •10. Platelet levels \< 150,000 or \> 450,000 per microliter;
• •11. Hemoglobin \< 12.0 g/dL (male) or \< 11.0 g/dL (female);
• •12. Prothrombin time \> 16s and activated partial thrombin time \> 35s in patients not accepting anticoagulant therapy; An international normalized ratio greater than 3 in patients accepting anticoagulant therapy;
• •13. Pregnancy (positive test) or lactation;
• •14. Participation in another simultaneous medical investigation or clinical trial;
• •15. Severe cicatricial eye disease; Conjunctival scarring with fornix shortening;
• •16. Ocular comorbidities that affect the prognosis of transplantation, such as advanced glaucoma or retinal diseases;
• •17. Severe dry eye disease as determined by Schirmer's test \< 2mm at least in one eye;
• •18. Any medical or social condition that in the judgment of the investigator would interfere with or serve as a contraindication to adherence to the study protocol or ability to give informed consent;
• •19. Signs of current infection, including fever and treatment with antibiotics;
• •20. Active immunological diseases;
• •21. History of allo-limbal transplantation, penetrating keratoplasty or anti-glaucoma filtering surgeries.